Sterile human placental allografts having a plurality of slits, openings, and/or fenestrations formed thereon
A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and/or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.
1. A sterile human placental allograft comprising a human amnion layer, an intact human intermediate spongy layer, and a human chorion layer, the sterile human placental allograft comprising interleukin-1 receptor antagonist (IL-1ra) ranging from 200 to 7800 pg/cm 2 and hepatocyte growth factor (HGF) ranging from 500 to 8500 pg/cm 2 ; and at least one of the following:
(a) vascular endothelial growth factor receptor 1 (VEGFR1) ranging from 800 to 2750 pg/cm 2 ;
(b) hyaluronic acid (HA) ranging from 5.0×10 6 to 1.5×10 8 pg/cm 2 ;
(c) platelet derived growth factor subunit B homodimer (PDGF-BB) ranging from 150 to 400 pg/cm 2 ;
(d) glycosaminoglycans (GAGs);
(e) collagen; and
(f) exosomes, wherein
the sterile placental allograft is intact in cross-section in which the human amnion layer and the human chorion layer have an intact human intermediate spongy layer positioned between and connecting the human amnion layer to the human chorion layer, and
the sterile placental allograft comprises a plurality of flaps formed through the sterile placental allograft, each flap of the plurality of flaps:
opens by moving in a direction away from the lower surface of the sterile human placental allograft allowing for wound exudate to flow from a wound and passing through the sterile human placental allograft in a direction from a lower surface of the sterile human placental allograft o an upper surface of the sterile human placental allograft to an upper surface of the sterile human placental allograft to facilitate wound drainage, wound healing, or a combination thereof, and
closes by moving in a direction towards the lower surface of the sterile human placental allograft such that no opening remains when each flap of the plurality of flaps is closed.
2. The sterile human placental allograft of claim 1 , wherein the sterile human placental allograft is configured for dental, cosmetic, and/or wound healing applications.
3. The sterile human placental allograft of claim 2 , wherein the sterile human placental allograft comprises a predetermined size of from 1 cm×1 cm to 8 cm×8 cm for rectangular and/or square shaped sterile human placental allografts and from 8 mm diameter to 50 mm diameter for circular shaped sterile human placental allografts.
4. The sterile human placental allograft of claim 3 , wherein the sterile human placental allograft comprises a circular shape, a square shape, a rectangular shape, an ovoid shape, a triangular shape, or any combination thereof.
5. The sterile human placental allograft of claim 1 , wherein the upper and lower surfaces of the sterile human placental allograft are planar.
6. The sterile human placental allograft of claim 1 , wherein flap moves in a direction away from the lower surface and the upper surface of the sterile human placental allograft when open.
7. The sterile human placental allograft of claim 6 , wherein the flap has a predetermined shape.
8. The sterile human placental allograft of claim 7 , wherein the predetermined shape is a “V” shape, a “U” shape, a semi-“U” shape, or combinations thereof.
9. The sterile human placental allograft of claim 7 , further comprising each of vascular endothelial growth factor receptor 1 (VEGFR1) ranging from 800 to 2750 pg/cm 2 ; hyaluronic acid (HA) ranging from 5.0×10 6 to 1.5×10 8 pg/cm 2 ; and platelet derived growth factor subunit B homodimer (PDGF-BB) ranging from 150 to 400 pg/cm 2 .
10. A kit comprising the sterile human placental allograft of claim 1 .
11. A method of treating a wound in a human subject in need thereof comprising contacting the wound with a sterile human placental allograft of claim 1 for a predetermined time period to facilitate wound healing in the human subject in need thereof.
12. The method of claim 11 , wherein the sterile human placental allograft is implanted in the subject in need thereof.
13. The method of claim 12 , wherein the wound is an internal wound within the subject in need thereof and/or a dental wound.
14. The method of claim 11 , wherein the sterile human placental allograft is topically applied to the wound in the human subject in need thereof.
15. The method of claim 11 wherein the wound is a diabetic ulcer.